Immuneering Corp.

General Information
Business:

Note: Immuneering Corp. is a preclinical biopharma company. From the prospectus:

“We are a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying our deep knowledge of translational bioinformatics to every stage of the drug development process. We have more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, we developed a disease-agnostic platform that enables us to utilize human data, novel biology and chemistry, and translational planning to create and advance our wholly owned pipeline. Our current development programs in oncology are focused on providing treatments for patients with solid tumors caused by mutations of the MAPK pathway and other oncologic signaling pathways.

“Our lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. We plan to submit an IND for IMM-1-104 to the FDA in the first quarter of 2022. In addition, we anticipate filing at least two additional INDs for our other oncology programs, one in each of 2023 and 2024.”

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 34
Founded: 2008
Contact Information
Address 245 Main Street, Second Floor Cambridge, Massachusetts 02142
Phone Number (617) 500-8080
Web Address
View Prospectus: Immuneering Corp.
Financial Information
Market Cap $358.35mil
Revenues $2.58 mil (last 12 months)
Net Income $-20.07 mil (last 12 months)
IPO Profile
Symbol IMRX
Exchange NASDAQ
Shares (millions): 7.5
Price range $15.00 - $15.00
Est. $ Volume $112.5 mil
Manager / Joint Managers Morgan Stanley/ Jefferies/ Cowen / Guggenheim Securities
CO-Managers -
Expected To Trade: 7/30/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change